![](/img/cover-not-exists.png)
METRO-BIBF Phase II, randomised, placebo controlled, multicentre, feasibility study of low dose (metronomic) cyclophosphamide (MCy) with and without nintedanib in advanced ovarian cancer (AOC)
Hall, M., Lillywhite, R., Nicum, S., Lord, R., Glasspool, R., Feeney, M., Hackshaw, A.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw374.51
Date:
October, 2016
File:
PDF, 38 KB
english, 2016